Recently, Salubris announced that the clinical trial application for its self-developed innovative small molecule drug SAL0139 tablets（Project code: SAL0139) has been officially accepted by the National Medical Products Administration (NMPA). This submission is intended for the treatment of hyperlipidemia[1].
Hyperlipidemia is a metabolic disorder characterized by its insidious onset and extensive health risks. Long-term uncontrolled hyperlipidemia can lead to multi-system complications, with low-density lipoprotein cholesterol (LDL-C)-related cholesterol accumulation being a key risk factor for cardiovascular and cerebrovascular diseases[2].
Preclinical studies have demonstrated that SAL0139 has the potential to reduce low-density lipoprotein cholesterol (LDL-C). If successfully developed and approved for market, this drug will provide hyperlipidemia patients with a new treatment option, further enriching the company's innovative product portfolio in the chronic disease fields, improving its solutions for cardiovascular and cerebrovascular chronic disease treatment, and enhancing its overall competitiveness in this field.
References:
[1] Announcement of Shenzhen Salubris Pharmaceuticals Co., Ltd. on the Acceptance of the Clinical Trial Application for Drug SAL0139
[2] Chinese Guidelines for Lipid Management (Primary Care Edition 2024)
Disclaimer:
1. This material is intended to provide knowledge in the field of disease, enhance disease awareness, and is not for promotional purposes.
2. The information contained herein is for reference only. Please follow the advice or guidance of physicians or other healthcare professionals.
About Salubris
Shenzhen Salubris Pharmaceuticals Co., Ltd., founded in 1998, is an innovation-driven pharmaceutical listed company (Stock Code: 002294) with integrated R&D, production, and marketing operations, rooted in China and serving the global market. With the mission of "providing exceptional pharmaceutical products for human health," Salubris has deepened its expertise in chronic disease treatment with a focus on cardiovascular and cerebrovascular conditions. The company has successfully commercialized alisartan monotherapy, combination drugs, and co-crystal formulations to address diverse complex hypertension challenges, establishing a unique family of first-in-class antihypertensive therapies centered on alisartan.
Salubris has established five innovative drug R&D centers and three medical device R&D bases globally, creating innovation platforms focused on small molecule drugs, biological drugs, siRNA therapeutics, gene-editing therapies, and medical devices. The company is committed to developing innovative products that address unmet clinical needs, with the goal of enhancing people's quality of life and extending healthy lifespan.
